Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded a net loss of $7.1 million for the quarter, compared to a loss of $1.9 million in the same period last year, marking an increase of 268%. For the first half of 2026, the net loss reached $13.3 million, up from $3.4 million in the first half of 2025. The increase in losses is attributed to heightened operating expenses, which surged to $6.4 million in Q2 2026 from $1.7 million in Q2 2025, driven primarily by increased research and development costs associated with the company's lead product candidate, Entolimod, and the operational costs of its newly acquired contract development and manufacturing organization (CDMO).
In terms of operational metrics, Valion's total assets as of June 30, 2026, stood at $32.5 million, a slight increase from $31.6 million at the end of 2025. However, cash and cash equivalents significantly decreased to $2.1 million from $12.6 million, raising concerns about the company's liquidity. The company reported a working capital of $336,000 and an accumulated deficit of $66.5 million. The substantial cash burn rate of $10.3 million in the first half of 2026, compared to $2.7 million in the same period of 2025, indicates a pressing need for additional financing to sustain operations and fund ongoing clinical trials.
Strategically, Valion has made notable advancements, including the acquisition of assets from Scorpius Holdings in December 2025, which has allowed the company to integrate its manufacturing capabilities in-house. This acquisition is expected to enhance operational efficiency and reduce reliance on third-party manufacturers. Additionally, the company has expanded its workforce to support its growth and reduce dependency on external service providers. In March 2026, Michael K. Handley was appointed as the new CEO, succeeding Jennifer Ernst, which reflects a shift in leadership aimed at steering the company through its transition into a biopharmaceutical entity.
Looking ahead, Valion anticipates continued operational losses as it invests in the development of Entolimod and its optimized variant, Entolasta. The company is actively seeking additional capital to fund its operations, including potential equity or debt offerings. Furthermore, Valion is under pressure to regain compliance with Nasdaq's minimum bid price requirement, having received a notification in March 2026 regarding its stock price falling below the required threshold. The company has until September 15, 2026, to address this issue, which could impact its listing status if not resolved. Overall, Valion's financial outlook remains uncertain, with significant challenges ahead as it navigates its growth trajectory in the biopharmaceutical sector.
About Valion Bio, Inc.
Tivic Health Systems develops non-invasive bioelectronic devices and biologics to treat immune and autonomic nervous system disorders. Its core products include FDA-approved sinus relief devices and advanced vagus nerve stimulation platforms. The company focuses on innovative, low-risk therapies for conditions like sinus pain, inflammation, and radiation syndrome, leveraging proprietary technology, strong IP, and regulatory pathways to address large healthcare markets.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov